Spyre Therapeutics Completes Recruitment for RA Sub-Study of SKYWAY Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 16 2026
0mins
Should l Buy SYRE?
Spyre Therapeutics announced the completion of recruitment for the RA sub-study of the SKYWAY basket trial and acceleration of expected topline readout to Q3 2026. "Enrollment in the RA sub-study of SKYWAY has exceeded our expectations and reflects both substantial unmet need as well as investigator enthusiasm for the potential of a long-acting anti-TL1A antibody," said Joshua Friedman, M.D., Ph.D., SVP of Clinical Development and SKYWAY study lead. "We look forward to delivering the first proof-of-concept data for this mechanism in rheumatic disease in the third quarter, with the potential to advance to pivotal trials next year. Together with readouts from the SKYLINE study, we now expect key data from Spyre's programs in IBD and rheumatic diseases in every subsequent quarter this year."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SYRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SYRE
Wall Street analysts forecast SYRE stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 51.770
Low
40.00
Averages
56.67
High
70.00
Current: 51.770
Low
40.00
Averages
56.67
High
70.00
About SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Stocks Reach New 52-Week Highs
- Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
- MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
- Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
- Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
See More
Spyre Therapeutics CEO Sells Shares Worth $740K
- Transaction Overview: Cameron Turtle, CEO of Spyre Therapeutics, sold 15,000 shares of common stock for approximately $740K on April 1, 2026, indicating active market engagement and liquidity for the company.
- Holding Proportion Analysis: This sale represented 2.33% of Turtle's direct holdings, consistent with his recent selling patterns since January 2026, reflecting ongoing management of his equity stake.
- Trading Context: Since May of last year, Turtle has executed six sales, with the 15,000-share size matching recent trade frequencies, demonstrating stability and liquidity management in the market.
- Clinical Progress Expectations: Spyre Therapeutics is accelerating its SKYWAY rheumatoid arthritis sub-study, expecting to deliver key clinical data in Q3 2026, showcasing the company's potential and growth opportunities in the biotechnology sector.
See More
Spyre Therapeutics CEO Sells Shares Worth $740K
- Executive Sell-off: Cameron Turtle, CEO of Spyre Therapeutics, sold 15,000 shares on April 1, 2026, for approximately $740K, representing a 2.33% reduction in direct holdings to 627,540 shares, indicating a routine profit-taking strategy.
- Transaction Context: The sale was executed under a Rule 10b5-1 trading plan established in June 2026, suggesting that this move reflects disciplined liquidity management rather than a shift in confidence regarding the company's fundamentals, especially after a 300% stock price increase over the past year.
- Clinical Advancements: Spyre has accelerated key clinical catalysts, with the SKYWAY rheumatoid arthritis sub-study expected to deliver topline data in Q3 2026, highlighting the company's robust growth potential in the biotechnology sector.
- Market Outlook: With the SKYLINE ulcerative colitis platform continuing to enroll and other studies on track, Spyre is set for a dense cadence of clinical updates, which will significantly support future value creation for the company.
See More
Spyre Therapeutics Grants Stock Options to Employees
- Stock Options Granted: On April 1, 2026, Spyre Therapeutics approved the grant of a total of 70,200 stock options to five non-executive employees as equity inducement awards under the 2018 Equity Inducement Plan, aimed at attracting and retaining talent to enhance team stability.
- Exercise Price Set: The granted stock options have an exercise price of $48.90 per share, equal to the closing price of Spyre's stock on April 1, 2026, reflecting the company's confidence in its future growth potential.
- Vesting Arrangement: The stock options vest with 1/4 becoming exercisable on the first anniversary of the employee's start date, followed by monthly vesting of 1/48, ensuring employees remain committed to the company to gain full benefits, thereby enhancing long-term employee engagement.
- Compliance Adherence: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), indicating the company's commitment to compliance and transparency in employee incentives, which helps bolster investor confidence.
See More
VR Adviser, LLC Increases Stake in Spyre Therapeutics by 1 Million Shares
- Share Increase: On February 17, 2026, VR Adviser, LLC disclosed the purchase of 1 million shares of Spyre Therapeutics, with an estimated trade value of $25.78 million based on quarterly average pricing, indicating strong confidence in the biotech firm.
- Value Growth: As of December 31, 2025, VR Adviser's total holding in Spyre Therapeutics reached $120.74 million, reflecting an increase of $75.73 million from the previous quarter, driven by both trading activity and share price appreciation.
- Portfolio Significance: Spyre Therapeutics now represents 5.96% of VR Adviser's 27-position U.S. equity portfolio, highlighting its importance within the fund, particularly under a strategy focused on biotechnology investments.
- Market Competitiveness: As a preclinical-stage biotechnology company, Spyre Therapeutics specializes in developing novel antibody therapies for inflammatory bowel disease, aiming to address significant unmet medical needs in gastrointestinal health, which positions it for long-term value creation.
See More
VR Adviser Increases Stake in Spyre Therapeutics by 1 Million Shares
- Share Acquisition: On February 17, 2026, VR Adviser, LLC disclosed the purchase of 1 million shares in Spyre Therapeutics, valued at approximately $25.78 million, reflecting the firm's confidence in the biotech company.
- Value Appreciation: As of December 31, 2025, VR Adviser's total holdings in Spyre reached 3,685,448 shares, valued at $120.74 million, with a quarter-end increase of $75.73 million, showcasing the dual impact of share price appreciation and trading activity.
- Portfolio Significance: Spyre Therapeutics now represents 5.96% of VR Adviser's reportable U.S. equity assets, highlighting its strategic importance within the firm's 27-position portfolio in the biotech sector.
- Strong Market Performance: As of March 18, 2026, Spyre's share price stood at $43.03, reflecting a 132.1% increase over the past year, significantly outperforming the S&P 500 by 115.4%, indicating robust market performance and investment appeal.
See More
Biotech Stocks Reach New 52-Week Highs
- Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
- MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
- Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
- Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
See More
Spyre Therapeutics CEO Sells Shares Worth $740K
- Transaction Overview: Cameron Turtle, CEO of Spyre Therapeutics, sold 15,000 shares of common stock for approximately $740K on April 1, 2026, indicating active market engagement and liquidity for the company.
- Holding Proportion Analysis: This sale represented 2.33% of Turtle's direct holdings, consistent with his recent selling patterns since January 2026, reflecting ongoing management of his equity stake.
- Trading Context: Since May of last year, Turtle has executed six sales, with the 15,000-share size matching recent trade frequencies, demonstrating stability and liquidity management in the market.
- Clinical Progress Expectations: Spyre Therapeutics is accelerating its SKYWAY rheumatoid arthritis sub-study, expecting to deliver key clinical data in Q3 2026, showcasing the company's potential and growth opportunities in the biotechnology sector.
See More
Spyre Therapeutics CEO Sells Shares Worth $740K
- Executive Sell-off: Cameron Turtle, CEO of Spyre Therapeutics, sold 15,000 shares on April 1, 2026, for approximately $740K, representing a 2.33% reduction in direct holdings to 627,540 shares, indicating a routine profit-taking strategy.
- Transaction Context: The sale was executed under a Rule 10b5-1 trading plan established in June 2026, suggesting that this move reflects disciplined liquidity management rather than a shift in confidence regarding the company's fundamentals, especially after a 300% stock price increase over the past year.
- Clinical Advancements: Spyre has accelerated key clinical catalysts, with the SKYWAY rheumatoid arthritis sub-study expected to deliver topline data in Q3 2026, highlighting the company's robust growth potential in the biotechnology sector.
- Market Outlook: With the SKYLINE ulcerative colitis platform continuing to enroll and other studies on track, Spyre is set for a dense cadence of clinical updates, which will significantly support future value creation for the company.
See More
Spyre Therapeutics Grants Stock Options to Employees
- Stock Options Granted: On April 1, 2026, Spyre Therapeutics approved the grant of a total of 70,200 stock options to five non-executive employees as equity inducement awards under the 2018 Equity Inducement Plan, aimed at attracting and retaining talent to enhance team stability.
- Exercise Price Set: The granted stock options have an exercise price of $48.90 per share, equal to the closing price of Spyre's stock on April 1, 2026, reflecting the company's confidence in its future growth potential.
- Vesting Arrangement: The stock options vest with 1/4 becoming exercisable on the first anniversary of the employee's start date, followed by monthly vesting of 1/48, ensuring employees remain committed to the company to gain full benefits, thereby enhancing long-term employee engagement.
- Compliance Adherence: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), indicating the company's commitment to compliance and transparency in employee incentives, which helps bolster investor confidence.
See More
VR Adviser, LLC Increases Stake in Spyre Therapeutics by 1 Million Shares
- Share Increase: On February 17, 2026, VR Adviser, LLC disclosed the purchase of 1 million shares of Spyre Therapeutics, with an estimated trade value of $25.78 million based on quarterly average pricing, indicating strong confidence in the biotech firm.
- Value Growth: As of December 31, 2025, VR Adviser's total holding in Spyre Therapeutics reached $120.74 million, reflecting an increase of $75.73 million from the previous quarter, driven by both trading activity and share price appreciation.
- Portfolio Significance: Spyre Therapeutics now represents 5.96% of VR Adviser's 27-position U.S. equity portfolio, highlighting its importance within the fund, particularly under a strategy focused on biotechnology investments.
- Market Competitiveness: As a preclinical-stage biotechnology company, Spyre Therapeutics specializes in developing novel antibody therapies for inflammatory bowel disease, aiming to address significant unmet medical needs in gastrointestinal health, which positions it for long-term value creation.
See More
VR Adviser Increases Stake in Spyre Therapeutics by 1 Million Shares
- Share Acquisition: On February 17, 2026, VR Adviser, LLC disclosed the purchase of 1 million shares in Spyre Therapeutics, valued at approximately $25.78 million, reflecting the firm's confidence in the biotech company.
- Value Appreciation: As of December 31, 2025, VR Adviser's total holdings in Spyre reached 3,685,448 shares, valued at $120.74 million, with a quarter-end increase of $75.73 million, showcasing the dual impact of share price appreciation and trading activity.
- Portfolio Significance: Spyre Therapeutics now represents 5.96% of VR Adviser's reportable U.S. equity assets, highlighting its strategic importance within the firm's 27-position portfolio in the biotech sector.
- Strong Market Performance: As of March 18, 2026, Spyre's share price stood at $43.03, reflecting a 132.1% increase over the past year, significantly outperforming the S&P 500 by 115.4%, indicating robust market performance and investment appeal.
See More
